Clinical Trial Update: HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA [Phase 1]

View source ↗

Summary

Phase 1 trial HESTIA evaluating HPV-16/18 E6/E7-specific T lymphocytes in relapsed HPV-associated cancers has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anal Cancer
• Cervical Cancer
• Oropharyngeal Cancer
• Penile Cancer
• Vulvar Cancer

Drugs mentioned

• HESTIA (HPV-16/18 E6/E7-specific T lymphocytes) (HPV-16/18 E6/E7-specific T lymphocytes)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Human Papillomavirus-Related Carcinoma, Human Papillomavirus Positive Oropharyngeal Carcinoma | Phase 1 | Status: COMPLETED